Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
TAK-438 - Safety, Blood Levels & Effects of Repeated Doses
Phase 1
Completed
- Conditions
- Erosive Esophagitis(EE)Gastroesophageal Reflux Disease (GERD)
- Interventions
- Drug: TAK-438 Placebo
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 48
- Registration Number
- NCT02141711
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects
Phase 1
Completed
- Conditions
- Dose Finding Study
- Interventions
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 73
- Registration Number
- NCT02141698
A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer
Phase 1
Completed
- Conditions
- Hormone Treatment-naïve Participants With Prostate Cancer
- Interventions
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 43
- Registration Number
- NCT02141659
Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Completed
- Conditions
- Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
- Interventions
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 292
- Registration Number
- NCT02139592
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
Phase 3
Completed
- Conditions
- Gout
- Interventions
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1790
- Registration Number
- NCT02139046
Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2816
- Registration Number
- NCT02134977
Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 122
- Registration Number
- NCT02129777
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment
Phase 2
Completed
- Conditions
- GoutModerate Renal Impairment
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 189
- Registration Number
- NCT02128490
- Locations
- 🇺🇸
Benny Green MD PA Family Practice, Little Rock, Arkansas, United States
🇺🇸Long Beach Center for Clinical Research, Long Beach, California, United States
🇺🇸Central Kentucy Reseach Associates, Lexington, Kentucky, United States
Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participants
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 108
- Registration Number
- NCT02123927
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 60
- Registration Number
- NCT02123953
© Copyright 2025. All Rights Reserved by MedPath